Edotreotide [CAS 204318-14-9]

Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) [1][2][3].

[204318-14-9]

C65H92N14O18S2

1421.64

O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](CO)[C@H](O)C)=O)NC([C@@]([C@H](O)C)([H])NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](NC(CN2CCN(CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6

Radionuclide-Drug Conjugates (RDCs)

Other

98.15

DMSO : 100 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Blue Ice